Clinical Trails

Please be aware that this page may not always be current. Updated information regarding clinical trials can be found searching for "desmoid tumor", “aggressive fibromatosis”, or even “fibromatosis.” at the National Cancer Institute’s website www.clinicaltrials.gov or Medpedia Project page at www.medpedia.com/clinical-trials

The following are ongoing or recently closed trials including desmoids:

NEW

A Phase 1B/II Study of GDC-0449 at Memorial Sloan- Kettering
This study is currently recruiting participants. 
Last Updated: February 2013
Sponsored by: Memorial Sloan-Kettering Cancer Center
Information provided by: Memorial Sloan-Kettering Cancer Center
Clinical Trials.gov Identifier: NSC 747691
For detailed information click here:

  

A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination with RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas   "Hedgehog" and "Notch" are examples of two groups of proteins that cause cancer cells to grow continuously.  GDC-0449 is a pill that blocks the activity of "Hedgehog" pathway.  RO4929097 is a pill that blocks the activity of "Notch" pathway.  Laboratory tests showed that a "Hedgehog" inhibitor and a "Notch" inhibitor were better when used together than when used alone. In order to study this you will be randomly assigned by a computer to get the Notch inhibitor alone or both Notch and Hedgehog inhibitor.  There is no sugar pills in this study.  All patients will get either one or two study drugs.   This is a phase II clinical trial.  The Phase I portion of the trial is already complete.  This is only available at MSKCC.     

Patients interested in joining should first be evaluated by any of the sarcoma doctors at MSKCC.

 


 

NEW

Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP) (CHIP)
This study is currently recruiting participants. 
Last Updated: November 2011
Sponsored by:

Pfizer
Information provided by: Pfizer
Clinical Trials.gov Identifier: NCT00585312

For detailed information click here:

 http://clinicaltrials.gov/ct2/show/NCT00585312

To compare the time from randomization to treatment failure over a 5 year period in subjects treated with celecoxib vs placebo.

The trial is currently enrolling subjects (10 to 17 years of age) with FAP and an intact colon into a study assessing the effectiveness and safety of Celebrex versus placebo in the prevention of colorectal polyps. If interested call Carol Burke, M. D. at 216/444-6864 or Hennie Hasson, R.N. at 216/444-6975.

Endoxifen in Adults With Hormone Receptor-Positive Solid Tumors
This study is currently recruiting participants. . 
Last Updated: March 2011
Sponsored by:

National Cancer Institute (NCI)
Information provided by: National Institutes of Health Clinical Center (CC)
Clinical Trials.gov Identifier: NCT01273168

For detailed information click here:

 http://www.clinicaltrials.gov/ct2/show /NCT01273168

To test the safety and effectiveness of daily endoxifen in individuals with hormone receptor-positive solid tumors that have not responded to standard treatment.


Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors
This study isongoing. 
Last Updated: June 2011
Sponsored by:

University of Pennsylvania
Information provided by: University of Pennsylvania
Clinical Trials.gov Identifier:

For detailed information click here:

The Role of Hydroxyurea as First Line Treatment for Primary Desmoid Tumors in Adults: You may be eligible to participate in this study if you have been diagnosed with a desmoid tumor and you have not been treated with chemotherapy. The study is being done to research how effective and safe the medication, hydroxyurea is in the treatment of desmoid tumors.

The Role of Hydroxyurea in the Treatment of Recurrent or Refractory Desmoid Tumors in Adults: You may be eligible to participate in this study if you have been diagnosed with a desmoid tumor and you have had chemotherapy in which the tumor did not respond. The study is being done to research how effective and safe the medication, hydroxyurea is in the treatment of desmoid tumors.

If you are eligible, you will take hydroxyurea, which is a tablet, by mouth daily. You will have to have an office visit every 4 weeks. You will have a CT scan or MRI every 12 weeks while on this study to help evaluate if the drug is effective. Patients will remain on the drug for up to one year as long as there is a response or stabiliy in tumor size and/or pain. If you are interested in more information, please contact Deb Riordan at 215-829-6712.

A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Firbromatosis
This study is currently recruiting participants.
Last Updated: December 21, 2010
Sponsored by:

University of Chicago
Information provided by: University of Chicago
Clinical Trials.gov Identifier: NCT01265030

For detailed information click here:

 http://clinicaltrials.gov/show/NCT01265030

Study to Evaluate Imatinib in Desmoid Tumors
This study is currently recruiting participants.
Last Updated: June 4, 2010
Sponsored by:

University of Heidelberg / Novartis
Information provided by: University of Heidelberg
Clinical Trials.gov Identifier: NCT01137916

For detailed information click here:

 http://clinicaltrials.gov/show/NCT01137916

Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
This study is currently recruiting participants.
Last Updated: May 12, 2010
Sponsored by:

The Cleveland Clinic / National Cancer Institute (NCI)
Information provided by: The Cleveland Clinic
Clinical Trials.gov Identifier: NCT00311558

For detailed information click here:

 http://clinicaltrials.gov/show/NCT00311558

Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate (PALANGI3)
This study is currently recruiting participants.
Last Updated: September 8, 2010
Sponsored by:

Centre Oscar Lambret
Information provided by: Centre Oscar Lambret
Clinical Trials.gov Identifier: NCT01046487

For detailed information click here:

 http://clinicaltrials.gov/show/NCT01046487

A Trial In Patients With Advanced Cancer And Leukemia
This study is currently recruiting participants (also open for desmoid tumor patients).
Last Updated: December 22, 2010
Sponsored by:

Pfizer
Information provided by: Pfizer
Clinical Trials.gov Identifier: NCT00878189

For detailed information click here:

 http://clinicaltrials.gov/show/NCT00878189

Imatinib in Patients With Desmoid Tumor and Chondrosarcoma (Basket 1)
This study is currently recruiting participants.
Last Updated: July 27, 2009
Sponsored by:

Italian Sarcoma Group
Information provided by: Italian Sarcoma Group
Clinical Trials.gov Identifier: NCT00928525

For detailed information click here:

 http://www.clinicaltrials.gov/ct2/show /NCT00928525

Radiation Therapy in Treating Patients with Aggressive Fibromatoses (Phase II)
This study is ongoing, but not recruiting participants.
Last Updated: February 6, 2009
Sponsored by:

European Organization for Research and Treatment of Cancer
Information provided by: National Cancer Institute (NCI)
Clinical Trials.gov Identifier: NCT00030680

For detailed information click here:

 http://www.clinicaltrials.gov/ct2/show /NCT00030680

Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), Last Updated: December 14, 2010
Sponsored by:

Children's Oncology Group National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
Clinical Trials.gov Identifier: NCT00919269

For detailed information click here:

http://www.clinicaltrials.gov/ ct2/show/NCT00919269

Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis (Phase I/II)
This study is currently recruiting participants.
Verified by National Cancer Institute (NCI) Last Updated: July 15, 2010
Sponsored by:

National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
Clinical Trials.gov Identifier: NCT00287846

For detailed information click here:

http://www.clinicaltrials.gov/ct2/show/NCT00287846

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This study has been completed.
Last Updated: November 4, 2010
Sponsored by:

Insys Therapeutics Inc
Information provided by: National Cancer Institute (NCI)
Clinical Trials.gov Identifier: NCT00538850

For detailed information click here:

 http://clinicaltrials.gov/show/NCT00538850

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
This study has been completed.
Last Updated: May 25, 2010
Sponsored by:

National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
Clinical Trials.gov Identifier: NCT00020579

For detailed information click here:

 http://clinicaltrials.gov/show/NCT00020579

Vinblastine and Methotrexate in Treating Children With Desmoid Tumors (Phase II)
This study has been completed.
Last Updated: November 2, 2010
Sponsored by:

National Cancer Institute (NCI)
Children's Cancer Group
Pediatric Oncology Group
Information provided by: National Cancer Institute (NCI)
Clinical Trials.gov Identifier: NCT00003019

For detailed information click here:

http://www.clinicaltrials.gov/ct2/ show/NCT00003019

Toremifene in Treating Patients With Desmoid Tumors (Phase II)
This study has been completed
Last Updated: September 1, 2010
Sponsored by:

Lutheran General Hospital
Information provided by: National Cancer Institute (NCI)
Clinical Trials.gov Identifier: NCT00002595

For detailed information click here:

http://www.clinicaltrials.gov/ ct2/show/NCT00002595

Sulindac and Tamoxifen in Treating Patients with Desmoid Tumors (Phase II)
This study has been completed.
Last Updated: December 14, 2010
Sponsored by:

Children's Oncology Group
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
Clinical Trials.gov Identifier: NCT00068419

For detailed information click here:

 http://www.clinicaltrials.gov/ct2/show/ NCT00068419

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas (Phase II)
This study has been completed.
Last Updated:October 16, 2009
Sponsored by:

Memorial Sloan-Kettering Cancer Center National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
Clinical Trials.gov Identifier: NCT00474994

For detailed information click here:

 http://www.clinicaltrials.gov/ct2/show/ NCT00474994